1.Risk Factors of Cerebral Infarction in Hypertensive and Non-hypertensive Patients
International Journal of Cerebrovascular Diseases 2006;0(06):-
Objective: To discuss the risk factors, subtypes and prognosis of cerebral infarction in hypertensive and non-hypertensive patients. Methods: A total of 976 patients with cerebral infarction were divided into hypertension (n=516) and non-hypertension (n=460) according to their history of hypertension. Single and multiple factor analysis in the risk factors, subtypes of cerebral infarct, and prognosis were performed. Results: The incidence of previous cerebral infarction, lacunar infarction, and posterior circulation infarction in the hypertension group was significantly higher than those in the non-hypertension group. Advanced age, cardiovascular diseases, and diabetes mellitus in the non-hypertension group were significantly more frequent than those in the hypertension group, and there were significant difference. Conclusions: Hypertension, diabetes mellitus, cardiovascular diseases, and advanced age are the main risk factors of cerebral infarction. Hypertension is the major causes of lacunar infarction and posterior circulation infarction.
2.NVP-TNKS656 inhibits the growth of hepatocellular carcinoma cell lines by regulating Hippo signaling pathway
Yu QIAO ; Zhehui HU ; Gang YU ; Beibei DUAN ; Shuai ZHANG ; Yunbo ZHAO ; Zijin ZHANG ; Lin LI
Chinese Journal of Geriatrics 2020;39(6):700-705
Objective:To investigate the effect of a tankyrase inhibitor NVP-TNKS656 on the growth of hepatocellular carcinoma(HCC)cell lines and the involved molecular mechanisms.Methods:Five HCC cell lines were treated with 0, 2.5, 5.0, 10.0 μmol/L of NVP-TNKS656.The cell lines of HLE and HLF were selected and divided into four groups: 0.0 μmol/L(control or DMSO), 2.5 μmol/L, 5.0 μmol/L, 10.0 μmol/L of NVP-TNKS656 groups.Cells were cultured for 48 h for subsequent experiments.Crystal violet staining was used to count the number of the newly formed cell clones.Western blotting was used to detect the protein expression levels of Yes-associated protein(YAP), angiomotin-like 1(AMOTL1)and AMOTL2.The real-time qRT-PCR was used to detect the mRNA expression of YAP and its downstream connective tissue growth factor(CTGF)and cysteine-rich 61(Cyr61). Dual luciferase reporter gene was used to detect the luciferase activity of transcriptional enhancer activator domain(TEAD)family.Results:NVP-TNKS656 inhibited the growth of 5 HCC cell lines in a dose-dependent manner in HLE, HLF, Huh7, MHCC97-H, and MHCC97-L cell lines.There were significant differences in the newly formed cell clone numbers between control(0 μM of NVP-TNKS656)and each of 2.5 μmol/L, 5.0 μmol/L, 10.0 μmol/L of NVP-TNKS656 groups in a dose-dependent manner( F=90.46, 68.58, 191.8, 114.6 and 201.4, all P<0.05). In HLE and HLF cell lines, NVP-TNKS656 significantly reduced the protein level of YAP in a dose-dependent manner and decreased the YAP target gene CTGF(HLE cells: 1.02±0.02, 0.90±0.03, 0.57±0.02, 0.38±0.03, HLF cells: 0.98±0.03, 0.86±0.02, 0.66±0.02, 0.43±0.01)and Cyr61(HLE cells: 1.00±0.01, 0.86±0.02, 0.74±0.03, 0.44±0.03 and HLF cells: 0.99± 0.02, 0.87±0.01, 0.72±0.02, 0.54±0.01)( P<0.05), and inhibited the activity of YAP/TEAD luciferase.At the same time, NVP-TNKS656 up-regulated two major negative regulators of YAP, namely AMOTL1 and AMOTL2 proteins, and promoted the apoptosis of HLE and HLF cells in a dose-dependent manner. Conclusion:NVP-TNKS656 can inhibit the proliferation of HCC by stabilizing AMOTL1/ AMOTL2 and down-regulating the YAP target gene.This study indicates that NVP-TNKS656 can be used as a potential drug for treating HCC.